North Carolina Specialty Pharmacy, Established NC Operator

$25.6M

Revenue

$1.1M

SDE

3.2x

Multiple

Subscribe Free

Read the full deal writeup

Get Free Access

Already a member? Sign in

Full Editorial Writeup

This is a well-established North Carolina specialty pharmacy generating $25.6M in annual revenue with $1.1M in EBITDA. Specialty pharmacies dispense high-cost, complex medications for chronic and rare conditions, which typically require prior authorizations, patient adherence management, and coordination with payers and prescribers. The listing emphasizes clean licensing and strong operations, both of which are non-trivial in a heavily regulated dispensing environment.

The business is being offered at $3.5M against $1.1M of EBITDA, a 3.19x multiple, which sits at the reasonable end for a healthcare services asset with recurring refill-driven revenue. Specialty pharmacies benefit from sticky patient panels: once a patient is established on a chronic therapy, they refill month after month, and payer relationships and network access create real switching friction.

The headline number to interrogate is the gap between $25.6M in revenue and $1.1M in EBITDA, a roughly 4.3% margin. That is characteristic of pharmacy economics where drug acquisition cost is the dominant expense and reimbursement spreads are thin. The buyer is really acquiring a licensed dispensing operation with volume and payer contracts, not a high-margin cash-flow machine, so the entire thesis rests on the durability and mix of that reimbursement.

Why we like it

Earnings quality is anchored in refill-driven volume. Specialty pharmacy revenue recurs because chronic-condition patients refill monthly, so the $25.6M top line is largely a returning panel rather than one-time transactions. That said, the thin 4.3% EBITDA margin means the earnings are volume and reimbursement sensitive, so quality depends heavily on payer contract stability.
The moat is regulatory and relational. Clean licensing, payer network access, and prior-authorization workflows are genuine barriers that take years and clean compliance history to build. A buyer inherits an operating platform that a new entrant could not stand up quickly, which is the real value behind the $3.5M ask.
Pharmacy demand is defensively positioned. Patients on chronic and specialty therapies do not stop taking their medications in a downturn, and much of the cost is carried by insurers rather than out of pocket. That makes the revenue base far more recession-resistant than typical retail.
The multiple is grounded. At 3.19x EBITDA, you are not overpaying for the cash flow, and the entry price leaves room for margin improvement to drive returns rather than betting on multiple expansion.

How to improve it

Audit and optimize the drug mix within the first 90 days. Shifting volume toward higher-margin specialty and limited-distribution drugs, while trimming low-reimbursement or below-cost SKUs, can meaningfully lift the 4.3% margin without adding revenue. This is the single highest-leverage lever in a thin-margin pharmacy.
Renegotiate or diversify PBM and payer contracts. Reimbursement spreads are set by pharmacy benefit managers, and even small improvements in contracted rates or DIR fee exposure flow straight to EBITDA. Map every payer's contribution and pursue better terms or additional network access on your most profitable therapies.
Tighten adherence and refill-synchronization programs. Higher patient adherence directly increases refill volume and improves payer quality metrics, which can unlock better rates. Systematizing refill reminders and med-sync reduces churn in the recurring patient panel.
Expand prescriber and referral relationships. Growth in specialty pharmacy is driven by getting on more prescriber referral pathways and payer-preferred networks. A focused outreach effort to local specialists and clinics can add patient starts without proportional overhead.
Build in prior-authorization and billing automation. PA denials and billing errors quietly erode margin in specialty dispensing. Investing in workflow software or a dedicated PA team improves capture rate and speeds cash conversion.
Pursue accreditation expansion. Adding URAC or ACHC specialty accreditations, if not already held, opens access to limited-distribution drugs and additional payer networks. This is a durable way to widen the moat and access higher-margin therapies.

Diligence notes

Verify revenue and EBITDA quality against pharmacy-specific accounting. Confirm how DIR fees, clawbacks, and rebates are treated, because these can materially reduce true net reimbursement and are often buried below reported EBITDA. Ask for a payer-level margin breakdown to understand where the $1.1M actually comes from.
Scrutinize customer and payer concentration. Determine what share of revenue comes from the top drugs, top prescribers, and each PBM contract, since loss of a single limited-distribution drug or a payer network exclusion could gut the top line. Concentration risk is the core threat in specialty pharmacy.
Confirm licensing, accreditation, and compliance history. The listing's 'clean licensing' claim must be verified through state board records, DEA registration, and any audit or recoupment history from payers. A hidden compliance issue or pending audit could impair the license, which is the entire asset.
Assess reimbursement trend and contract renewal risk. Review historical reimbursement per script over the last three years to see whether spreads are compressing, and check the renewal dates and terms on major PBM contracts. Thin margins mean small reimbursement cuts can turn profit into loss.
Clarify years in business, ownership involvement, and transition terms. The listing does not disclose founding year, owner role, or any transition support, all of which are material to continuity of payer relationships and the pharmacist-in-charge license. Confirm whether key staff and the PIC will stay post-close.

Source

Originally listed on DealStream. View original listing →